Atossa Therapeutics, Inc. (ATOS) has 18 tenedores institucionales e internos conocidos registrados. El mayor tenedor es Guse Kyle con 557,900 acciones. Otros tenedores destacados incluyen Rees Heather y Chen Ben R.
En los últimos 12 meses, los internos han realizado 15 transacciones en ATOS acciones — 14 compras (valoradas en $3.24M) y 0 ventas (valoradas en RSU Award). Las compras internas han superado las ventas durante este período, lo que puede señalar confianza en las perspectivas de la empresa.
ATOS Participación de Insiders
Principal Titular
Guse Kyle
557,900 acciones
Compras (12 meses)
14
$3.24M valor
Ventas (12 meses)
0
$0.00 valor
Actividad de Transacciones (12 meses)
Principales Titulares Internos
| # |
Nombre |
Cargo |
Acciones en Propiedad |
Última Declaración |
Tamaño Relativo |
| 1 |
Guse Kyle |
CFO, Gen Counsel and Secretary |
557,900 |
2023-03-06 |
|
| 2 |
Rees Heather |
Chief Financial Officer |
543,785 |
2025-05-16 |
|
| 3 |
Chen Ben R |
Sr. VP of Glob. Reg. Affairs |
300,000 |
2014-04-03 |
|
| 4 |
Youmans Scott |
Chief Operating Officer |
286,217 |
2015-09-03 |
|
| 5 |
Chen Shu-chih |
Director |
125,000 |
2025-05-16 |
|
| 6 |
Finn Jonathan |
Director |
125,000 |
2025-05-16 |
|
| 7 |
Remmel H. Lawrence |
Director |
125,000 |
2025-05-16 |
|
| 8 |
Steinhart Richard I |
Director |
125,000 |
2025-05-16 |
|
| 9 |
Cigler Tessa |
Director |
125,000 |
2025-05-16 |
|
| 10 |
Galli Stephen J |
Director |
125,000 |
2025-05-16 |
|
| 11 |
Cross Alexander D |
Director |
88,866 |
2013-06-27 |
|
| 12 |
Quay Steven C |
President & CEO |
88,038 |
2026-03-31 |
|
| 13 |
Daniel Mark James |
Chief Financial Officer |
63,000 |
2026-03-30 |
|
| 14 |
Sawyer John E |
See Remarks |
59,265 |
2015-03-18 |
|
| 15 |
Destro Christopher S. |
SVP, Sales and Marketing |
54,625 |
2015-03-18 |
|
| 16 |
Carbonaro Peter J. |
Sr. Vice President, Operations |
45,000 |
2014-05-08 |
|
| 17 |
Barnhart John |
Director |
44,882 |
2013-05-09 |
|
| 18 |
Weaver Gregory L |
Former EVP, CFO, & Director |
55 |
2023-11-17 |
|
Transacciones Recientes (últimos 12 meses)
| Fecha |
Nombre |
Cargo |
Tipo |
Acciones |
Precio |
Valor |
| 2026-03-27 |
Quay Steven C |
President & CEO |
Concesión de RSU |
65,000 |
- |
- |
| 2026-03-26 |
Daniel Mark James |
Chief Financial Officer |
Concesión de RSU |
63,000 |
- |
- |
| 2026-01-20 |
Quay Steven C |
President & CEO |
Concesión de RSU |
331,674 |
- |
- |
| 2026-01-20 |
Quay Steven C |
President & CEO |
Concesión de RSU |
325,203 |
- |
- |
| 2025-10-14 |
Daniel Mark James |
Chief Financial Officer |
Concesión de RSU |
578,000 |
$1.03 |
$595.34K |
| 2025-10-14 |
Daniel Mark James |
Officer |
Desconocido |
- |
- |
- |
| 2025-05-21 |
Quay Steven C |
President & CEO |
Compra Informativa |
11,239 |
$0.88 |
$9.89K |
| 2025-05-15 |
Cigler Tessa |
Director |
Concesión de RSU |
125,000 |
$0.99 |
$123.75K |
| 2025-05-15 |
Rees Heather |
Chief Financial Officer |
Concesión de RSU |
543,785 |
$0.99 |
$538.35K |
| 2025-05-15 |
Finn Jonathan |
Director |
Concesión de RSU |
125,000 |
$0.99 |
$123.75K |
| 2025-05-15 |
Chen Shu-chih |
Director |
Concesión de RSU |
125,000 |
$0.99 |
$123.75K |
| 2025-05-15 |
Galli Stephen J |
Director |
Concesión de RSU |
125,000 |
$0.99 |
$123.75K |
| 2025-05-15 |
Remmel H. Lawrence |
Director |
Concesión de RSU |
125,000 |
$0.99 |
$123.75K |
| 2025-05-15 |
Steinhart Richard I |
Director |
Concesión de RSU |
125,000 |
$0.99 |
$123.75K |
| 2025-05-15 |
Quay Steven C |
President & CEO |
Concesión de RSU |
1,366,062 |
$0.99 |
$1.35M |
